The rheumatoid arthritis drugs market size achieved a value of USD 17.87 billion in 2023 with this trajectory, it is expected to reach USD 27.38 billion by 2033. Projected growth indicates a compound annual growth rate (CAGR) of 4.6% over the forecast period.
Download a sample of this report @ https://www.towardshealthcare.com/download-statistics/5122
Due to the rising rheumatoid arthritis population, the CDC organized a program to help manage and improve the well-being of those with the condition. Between 2019 and 2021, about 24.2% of women and 17.9% of men in the United States were told by a doctor that they had arthritis.
Rheumatoid arthritis is a type of arthritis that happens when your immune system mistakenly attacks the lining of your joints, called the synovium. This causes inflammation, pain, stiffness, and swelling in the affected joints. Over time, this inflammation can damage the joints and lead to deformities or loss of function. Rheumatoid arthritis commonly affects the hands, wrists, and knees but can also affect other joints. It’s a chronic condition, meaning it usually lasts a long time and requires ongoing management to control symptoms and prevent joint damage.
Rheumatoid arthritis is a progressive disease, meaning it can get worse over time if not treated. It can damage your joints, making them deformed and difficult to move. If detected early and managed correctly, the worsening of the disease can often be slowed down or stopped. We’re not sure what causes rheumatoid arthritis, but things like your genes, environment, and hormones might play a role. Women tend to get rheumatoid arthritis more than men. To diagnose rheumatoid arthritis, doctors will ask about your symptoms, examine your joints, and do some blood tests and imaging tests like X-rays or ultrasound to see how much damage there is.
Recent Developments
- In July 2023, Biocon Biologics Ltd, a part of Biocon Ltd, said they had made HULIO (adalimumab fijp) injection available in the US. It’s similar to Humira (adalimumab) and is used to treat rheumatoid arthritis.
- In February 2022, Pfizer Inc. shared that the US Food and Drug Administration (FDA) agreed to review their application for ABRILADA (adalimumab-afib). They want it to be recognized as a biosimilar drug to Humira (adalimumab) that can be swapped with the original.
- In February 2022, Biogen Inc. and Xbrane Biopharma AB collaborated to develop, make, and sell Xcimzane. This drug is still in the testing phase but aims to be like CIMZIA (certolizumab pegol), another medicine used for rheumatoid arthritis.
Market Players
- Boehringer Ingelheim GmbH
- AbbVie
- Novartis
- Pfizer Inc
- Bristol Mayers Squib
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Regeneron Pharmaceuticals, Inc
- Amgen, Inc.
- Merck KGaA
Market Segments
By Drug Type
- Pharmaceuticals
- NSAIDs
- Analgesics
- DMARDs
- Glucocorticoids
- Biopharmaceuticals
- Biologics
- TNF-α Antagonists
- T-cell Inhibitors
- CD20 Antigen
- JAK Inhibitors
- Anti-IL6 Biologics
- Biosimilars
- CD20 Antigen
- TNF-α Antagonists
- Biologics
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Route of Administration
- Oral
- Parenteral
- Topical
By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Explore in-depth: https://www.healthcarewebwire.com/cell-therapy-manufacturing-market/
Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/rheumatoid-arthritis-drugs-market-sizing
To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5122
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
